JAK1/CDK7-IN-1 

JAK1/CDK7-IN-1 (compound 11) is a JAK1/CDK7 inhibitor and cytotoxic agent.JAK1/CDK7-IN-1 forms a stable, tightly bound complex with JAK1.JAK1/CDK7-IN-1 disrupts cell cycle, induces G₂/M phase arrest, and increases Pre-G₁ phase cell proportion.JAK1/CDK7-IN-1 induces apoptosis, elevates caspase 1, 3, and 9 levels, and triggers apoptotic and necrotic cell death.JAK1/CDK7-IN-1 can be used for the research of breast cancer, prostate cancer^[1].

JAK1/CDK7-IN-1 (compound 11) (tested across concentrations; 24 h) potently inhibits the proliferation of MCF-7, MDA-MB-231, and PC-3 cancer cells with IC₅₀ values of 2.85, 4.61, and 7.69 µM respectively, and demonstrates selective toxicity toward cancer cells over normal WI-38 cells^[1].
JAK1/CDK7-IN-1 potently inhibits JAK1 enzyme activity in MCF-7, MDA-MB-231, and PC-3 cells with IC₅₀ values of 0.017, 0.01, and 0.10 µM respectively^[1].
JAK1/CDK7-IN-1 inhibits CDK7 enzyme activity by 80.7% in MCF-7 cells, 68.1% in MDA-MB-231 cells, and 83.4% in PC-3 cells^[1].
JAK1/CDK7-IN-1 upregulates apoptosis-associated caspase levels in cancer cells, with 4.60-, 3.03-, and 2.69-fold increases in caspase-1, -3, and -9 respectively in MDA-MB-231 cells, a 3.50-fold increase in caspase-1 in PC-3 cells, and 2.87- and 1.08-fold increases in caspase-1 and -9 respectively in MCF-7 cells^[1].
JAK1/CDK7-IN-1 induces G₂/M phase cell cycle arrest and pre-G₁ apoptosis in MCF-7 cells, increasing G₂/M phase cells to 35.03% and pre-G₁ phase cells to 20.68%^[1].
JAK1/CDK7-IN-1 significantly induces apoptosis and necrosis in MCF-7 cells, increasing total apoptosis to 10.92% and necrosis to 3.47%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

533.43

C₂₇H₁₈Cl₂N₄O₂S

O=C(NC1=CC=C(/N=C/C2=CC(C3=CC=CS3)=NN2C4=CC=CC=C4)C=C1Cl)C5=CC(Cl)=CC=C5O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ismail MMF, et al. Novel niclosamide-derived Schiff bases as a dual-targeted anticancer agents. Sci Rep. 2026;16(1):1959. Published 2026 Jan 13.  [Content Brief]